Epigenetic drug discovery and cancer research by Foghorn Therapeutics

  • Eugene Komchuk
  • 20 hours ago
Pipeline advances outlined by Foghorn Therapeutics in Q3 2026 update
Foghorn Therapeutics issued an update for the third quarter of 2026, citing continued progress across its oncology and immunology and inflammation pipeline. Key areas of advancement include its ...
  • Mikhail Vnuchkov
  • 06.08.2026
Foghorn Therapeutics advances FHD-909 with Lilly and launches oral immunology program in Q2 update
Foghorn Therapeutics announced continued progress across its development pipeline in its Q2 2026 update. Key highlights include the advancement of FHD-909 (LY4050784) in collaboration with Lilly ...
  • Hanna Syniavska
  • 12.05.2026
Foghorn Therapeutics schedules trio of investor events to spotlight oncology developments
Foghorn Therapeutics will participate in three investor conferences this month to update stakeholders on its progress across its first-in-class oncology pipeline. The company aims to engage the ...